The P1 monotherapy vaccine increased the proportion of cDC1 and cDC2 subsets in the lymph nodes, which presented antigens to CD8+ T cells and CD4+ T cells, respectively, promoting the activation and differentiation of T cells in the dLN and generating a potent anti-tumor immune response [68,69,70,71,72]. The gene discussed is CD8A; the disease is neoplasm.